Explore more publications!
California Commerce Daily
Got News to Share?

California Commerce Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Commerce Daily.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 7, 2025

PROPSTORE ACHIEVES $10.2 MILLION IN DAY ONE RESULTS AS LONDON ENTERTAINMENT MEMORABILIA AUCTION OPENS STRONGLY
December 7, 2025

PROPSTORE ACHIEVES $10.2 MILLION IN DAY ONE RESULTS AS LONDON ENTERTAINMENT MEMORABILIA AUCTION OPENS STRONGLY

Indeterminate EIN Presswire
COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.
December 7, 2025

COGNNA announces a $9.2M Series A led by Impact46 with participation from BNVTCapital, VisionVentures, and TaliVentures.

Indeterminate EIN Presswire
Zensa Skin Care Expands Its Presence in Aesthetic Clinics Nationwide
December 7, 2025

Zensa Skin Care Expands Its Presence in Aesthetic Clinics Nationwide

Indeterminate EIN Presswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Indeterminate GlobeNewswire
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 7, 2025

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

Indeterminate GlobeNewswire
Les forages recoupent une large zone minéralisée dans un nouveau secteur bien en dehors des ressources
December 7, 2025

Les forages recoupent une large zone minéralisée dans un nouveau secteur bien en dehors des ressources

Indeterminate GlobeNewswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 7, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Indeterminate GlobeNewswire
Rally House Breaks Company Online Sales Record After Electric Sports Weekend
December 7, 2025

Rally House Breaks Company Online Sales Record After Electric Sports Weekend

Indeterminate GlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 7, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Indeterminate GlobeNewswire
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
December 7, 2025

SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions